Commission Regulation (EU) No 618/2012 of 10 July 2012 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures Text with EEA relevance

Regulation (EU) No 618/2012 · Regulation · 6 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows: (1) Table 3.1 is amended as follows: (a) The entries corresponding to the entries set out in Annex I are replaced by the entries set out in that Annex; (b) The entries set out in Annex II are inserted in accordance with the order of the entries set out in Table 3.1. (2) Table 3.2 is amended as follows: (a) The entries corresponding to the entries set out in Annex III are replaced by the entries set out in that Annex; (b) The entries set out in Annex IV are inserted in accordance with the order of the entries set out in Table 3.2.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . Article 1 shall apply from 1 December 2013. The harmonised classifications set out in Part 3 of Annex VI to Regulation (EC) No 1272/2008, as amended by this Regulation, may be applied before 1 December 2013.

Supplementary provisions

ANNEX ISupplementary provisions

ANNEX I Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard Statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) "009-016-00-2 trisodium hexafluoroaluminate [1] 237-410-6 [1] 13775-53-6 [1] STOT RE 1 Acute Tox. 4 Aquatic Chronic 2 H372 H332 H411 GHS07 GHS08 GHS09 Dgr H372 H332 H411 trisodium hexafluoroaluminate (cryolite) [2] 239-148-8 [2] 15096-52-3 [2] 603-012-00-X 2-ethoxyethanol; ethylene glycol monoethyl ether 203-804-1 110-80-5 Flam. Liq. 3 Repr. 1B Acute Tox. 3 Acute Tox. 4 H226 H360FD H331 H302 GHS02 GHS08 GHS06 Dgr H226 H360FD H331 H302 603-025-00-0 tetrahydrofuran 203-726-8 109-99-9 Flam. Liq. 2 Carc. 2 Eye Irrit. 2 STOT SE 3 H225 H351 H319 H335 GHS02 GHS07 GHS08 Dgr H225 H351 H319 H335 EUH019 STOT SE 3; H335: C ≥ 25 % Eye Irrit.2; H319: C ≥ 25 % 613-016-00-3 fuberidazole (ISO); 2-(2-furyl)-1 H -benzimidazole 223-404-0 3878-19-1 Carc. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H373 (heart) H317 H400 H410 GHS07 GHS08 GHS09 Wng H351 H302 H373 (heart) H317 H410 M = 1 617-001-00-2 di- tert -butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H225 H341 GHS02 GHS08 Dgr H242 H225 H341"

ANNEX IISupplementary provisions

ANNEX II Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard Statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘015-199-00-X tris[2-chloro-1-chloromethyl)ethyl] phosphate 237-159-2 13674-87-8 Carc. 2 H351 GSH08 Wng H351 015-200-00-3 indium phosphide 244-959-5 22398-80-7 Carc. 1B Repr. 2 STOT RE 1 H350 H361f H372 (lungs) GHS08 Dgr H350 H361f H372 (lungs) STOT RE 1; H372: C ≥0,1 % Carc 1B; H350: C ≥0,01 % STOT RE 2; H373: 0,01 % ≤ C < 0,1 % 015-201-00-9 trixylyl phosphate 246-677-8 25155-23-1 Repr. 1B H360F GHS08 Dgr H360F 015-202-00-4 tris(nonylphenyl) phosphite 247-759-6 26523-78-4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410 015-203-00-X diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 278-355-8 75980-60-8 Repr. 2 H361f (causing atrophy of the testes) GHS08 Wng H361f (causing atrophy of the testes) 602-109-00-4 Hexabromocyclododecane [1] 247-148-4 [1] 25637-99-4[1] Repr. 2 Lact. H361 H362 GHS08 Wng H361 H362 1,2,5,6,9,10-hexabromocyclododecane [2] 221-695-9[2] 3194-55-6[2] 606-143-00-0 abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] _ [1] 71751-41-2 [1] Repr. 2 Acute Tox. 2 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H361d H300 H330 H372 (nervous system) H400 H410 GHS06 GHS08 GHS09 Dgr H361d H300 H330 H372 (nervous system) H410 STOT RE 1; H372: C ≥ 5 % STOT RE 2; H373: 0,5 % ≤C<5 % M = 10 000 avermectin B1a (purity ≥80 %); [2] 265-610-3 [2] 65195-55-3 [2] 606-144-00-6 acequinocyl (ISO); 3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate — 57960-19-7 Skin Sens. 1 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H317 H370 (lung) (inhalation) H373 (blood system) H400 H410 GHS07 GHS08 GHS09 Dgr H317 H370 (lung) (inhalation) H373 (blood system) H410 M = 1 000 607-698-00-1 4- tert -butylbenzoic acid 202-696-3 98-73-7 Repr. 1B STOT RE 1 Acute Tox. 4 H360F H372 H302 GHS07 GHS08 Dgr H360F H372 H302 612-281-00-2 leucomalachite green; N,N,N',N'-tetramethyl-4,4'-benzylidenedianiline 204-961-9 129-73-7 Carc. 2 Muta. 2 H351 H341 GHS08 Wng H351 H341 616-205-00-9 Metazachlor (ISO); 2-chloro-N-(2,6-dimethylphenyl)-N-(1H-pyrazol-1-ylmethyl)acetamide 266-583-0 67129-08-2 Skin Sens. 1B Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H317 H351 H400 H410 GHS07 GHS08 GHS09 Wng H317 H351 H410 M = 100 M = 100’

ANNEX IIISupplementary provisions

ANNEX III Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes "009-016-00-2 trisodium hexafluoroaluminate [1] 237-410-6 [1] 13775-53-6 [1] Xn; R20 T; R48/23/25 N; R51-53 T; N R: 20-48/23/25-51/53 S: (1/2-)22-37-45-61 trisodium hexafluoroaluminate (cryolite) [2] 239-148-8 [2] 15096-52-3 [2] 603-012-00-X 2-ethoxyethanol; ethylene glycol monoethyl ether 203-804-1 110-80-5 R10 Repr. Cat. 2; R60-61 Xn; R20/22 T R: 60-61-10-20/22 S: 53-45 E 603-025-00-0 tetrahydrofuran 203-726-8 109-99-9 F; R11-19 Carc. Cat. 3; R40 Xi; R36/37 F; Xn R: 11-19-40-36/37 S: (2-)(13-)16-29-33-36-37(-46) Xi; R36/37: C ≥ 25 % 613-016-00-3 fuberidazole (ISO); 2-(2-furyl)-1 H -benzimidazole 223-404-0 3878-19-1 Carc. Cat. 3; R40 Xn; R48/22 Xn; R22 Xi; R43 N; R50-53 Xn; N R: 40-48/22-22-43-50/53 S: (2)-22-36/37-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 617-001-00-2 di- tert -butyl peroxide 203-733-6 110-05-4 O; R7 F; R11 Muta. Cat. 3, R68 O; F; Xn R: 7-11-68 S: (2-)3/7-14-16-23-36/37/39"

ANNEX IVSupplementary provisions

ANNEX IV Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes ‘015-199-00-X tris[2-chloro-1-chloromethyl)ethyl] phosphate 237-159-2 13674-87-8 Carc. Cat. 3; R40 Xn R: 40 S: (2-)36/37 015-200-00-3 indium phosphide 244-959-5 22398-80-7 Carc. Cat. 2; R45 Repr. Cat. 3; R62 T; R48/23 T R: 45–48/23–62 S: 45- 53 T; R48/23: C ≥0,1% Carc Cat 2; R45: C ≥0,01% Xn; R48/20: 0,01%≤ C < 0,1% E 015-201-00-9 trixylyl phosphate 246-677-8 25155-23-1 Repr. Cat. 2; R60 T R: 60 S: 53-45 015-202-00-4 tris(nonylphenyl) phosphite 247-759-6 26523-78-4 Xi; R43 N; R50-53 Xi; N R: 43-50/53 S: 24-37-60-61 015-203-00-X diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 278-355-8 75980-60-8 Repr. Cat. 3; R62 Xn R: 62 S: (2)-22-36/37. 602-109-00-4 Hexabromocyclododecane [1] 247-148-4 [1] 25637-99-4[1] Repr. Cat. 3; R63 R64 Xn R: 63-64 S: 36/37-53 1,2,5,6,9,10-hexabromocyclododecane [2] 221-695-9[2] 3194-55-6[2] 606-143-00-0 abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] _ [1] 71751-41-2 [1] Repr. Cat. 3; R63 T+; R26/28 T; R48/23/25 N; R50-53 T+; N R: 63-26/28-48/23/25-50/53 S: 28-36/37-45-60-61 T; R48/23: C ≥ 5% Xn; R48/20: 0,5% ≤ C <5% N; R50-53: C ≥ 0,0025% N; R51-53: 0,00025% ≤ C <0,0025% R52-53: 0,000025% ≤ C<0,00025% avermectin B1a (purity ≥80%); [2] 265-610-3 [2] 65195-55-3 [2] 606-144-00-6 acequinocyl (ISO); 3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate — 57960-19-7 T; R39/23 Xi; R43 N; R50-53 T; N R: 39/23-43-50/53, S: (2-)24-37-38-60-61 N; R50-53: C ≥ 0,025% N; R51-53: 0,0025% ≤ C < 0,025% R52-53: 0,00025% ≤ C < 0,0025% 607-698-00-1 4- tert -butylbenzoic acid 202-696-3 98-73-7 Repr. Cat. 2; R60 T; R48/23/24/25 Xn; R22 T R: 60-22-48/23/24/25 S: 53-45 E 612-281-00-2 leucomalachite green N,N,N',N'-tetramethyl-4,4'-benzylidenedianiline 204-961-9 129-73-7 Carc. Cat. 3; R40 Muta. Cat. 3; R68 Xn R: 40-68 S: (2-)36/37 616-205-00-9 Metazachlor (ISO); 2-chloro-N-(2,6-dimethylphenyl)-N-(1H-pyrazol-1-ylmethyl)acetamide 266-583-0 67129-08-2 R43 Carc. Cat. 3; R40 N; R50-53 Xn; N R: 40-43-50/53 S: (2-)36-37-60-61 N; R50-53: C ≥ 0,25% N; R51-53: 0,025% ≤ C < 0,25% R52-53: 0,0025% ≤ C < 0,025%’

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview